keyword
MENU ▼
Read by QxMD icon Read
search

Asthma immunotherapy

keyword
https://www.readbyqxmd.com/read/28223739/effectiveness-of-specific-sublingual-immunotherapy-in-korean-patients-with-atopic-dermatitis
#1
Hyang-Suk You, Min-Young Yang, Gun-Wook Kim, Hyun-Ho Cho, Won-Jeong Kim, Je-Ho Mun, Margaret Song, Hoon-Soo Kim, Hyun-Chang Ko, Moon-Bum Kim, Byung-Soo Kim
BACKGROUND: Sublingual immunotherapy (SLIT) with house dust mites (HDM) preparation has recently been proven to be beneficial for treating allergic rhinitis and asthma. However, there has been no report regarding the efficacy and safety of SLIT in Korean patients with atopic dermatitis (AD). OBJECTIVE: We intended to investigate the efficacy and safety of SLIT in Korean patients with AD. METHODS: A total of 34 patients with AD and immunoglobulin E (IgE)-proven HDM sensitization (Class ≥3) were recruited...
February 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28199353/oral-administration-of-lactobacillus-paracasei-l9-attenuates-pm2-5-induced-enhancement-of-airway-hyperresponsiveness-and-allergic-airway-response-in-murine-model-of-asthma
#2
Xifan Wang, Yan Hui, Liang Zhao, Yanling Hao, Huiyuan Guo, Fazheng Ren
This study investigated allergy immunotherapy potential of Lactobacillus paracasei L9 to prevent or mitigate the particulate matter 2.5 (PM2.5) enhanced pre-existing asthma in mice. Firstly, we used a mouse model of asthma (a 21-day ovalbumin (OVA) sensitization and challenge model) followed by PM2.5 exposure twice on the same day of the last challenge. PM2.5 was collected from the urban area of Beijing and underwent analysis for metals and polycyclic aromatic hydrocarbon contents. The results showed that PM2...
2017: PloS One
https://www.readbyqxmd.com/read/28188713/-safety-of-subcutaneous-immunotherapy-with-tyrosine-adsorbed-house-dust-mite-extracts-in-patients-with-allergic-disease
#3
Mónica María Molina-Sáenz, Ana María Villa-Arango, Ricardo Cardona-Villa
BACKGROUND: In spite of allergen-specific immunotherapy (SIT) multiple benefits, its use is restricted in some countries owing to concerns about severe adverse reactions. OBJECTIVE: To evaluate systemic adverse reactions in patients with atopic dermatitis, allergic asthma, allergic rhinitis and allergic conjunctivitis who received subcutaneous immunotherapy with tyrosine-adsorbed Dermatophagoides and Glycyphagoides dust mites extracts. METHODS: Retrospective study of the 2010-2015-period that included 773 patients diagnosed with IgE-mediated diseases, where the safety of allergen-specific immunotherapy was described according to the World Organization of Allergy subcutaneous immunotherapy-induced systemic reactions classification system...
January 2017: Revista Alergia Mexico: Organo Oficial de la Sociedad Mexicana de Alergia e Inmunología, A.C
https://www.readbyqxmd.com/read/28152201/biomarkers-for-monitoring-clinical-efficacy-of-allergen-immunotherapy-for-allergic-rhinoconjunctivitis-and-allergic-asthma-an-eaaci-position-paper
#4
M H Shamji, J H Kappen, M Akdis, E Jensen-Jarolim, E F Knol, J Kleine-Tebbe, B Bohle, A M Chaker, S J Till, R Valenta, L K Poulsen, M A Calderon, P Demoly, O Pfaar, L Jacobsen, S R Durham, C B Schmidt-Weber
Allergen immunotherapy (AIT) is an effective treatment for allergic rhinoconjunctivitis (AR) with or without asthma (1-12). AIT has disease modifying properties and confers long-term clinical benefit after cessation of treatment (6, 7, 13-17). AIT is routinely used in daily practice and can be administered either subcutaneously (SCIT) or sublingually (SLIT) (3-12). Although AIT is effective, the degree of remission strongly varies depending on the complex interaction between patient, allergy, symptomatology and vaccines used for AIT (3-9)...
February 2, 2017: Allergy
https://www.readbyqxmd.com/read/28128443/potential-therapeutic-applications-of-adenosine-a2a-receptor-ligands-and-opportunities-for-a2a-receptor-imaging
#5
REVIEW
Aren van Waarde, Rudi A J O Dierckx, Xiaoyun Zhou, Shivashankar Khanapur, Hideo Tsukada, Kiichi Ishiwata, Gert Luurtsema, Erik F J de Vries, Philip H Elsinga
Adenosine A2A receptors (A2A Rs) are highly expressed in the human striatum, and at lower densities in the cerebral cortex, the hippocampus, and cells of the immune system. Antagonists of these receptors are potentially useful for the treatment of motor fluctuations, epilepsy, postischemic brain damage, or cognitive impairment, and for the control of an immune checkpoint during immunotherapy of cancer. A2A R agonists may suppress transplant rejection and graft-versus-host disease; be used to treat inflammatory disorders such as asthma, inflammatory bowel disease, and rheumatoid arthritis; be locally applied to promote wound healing and be employed in a strategy for transient opening of the blood-brain barrier (BBB) so that therapeutic drugs and monoclonal antibodies can enter the brain...
January 27, 2017: Medicinal Research Reviews
https://www.readbyqxmd.com/read/28121746/respiratory-difficulties-in-children-with-underlying-asthma-during-immunotherapy-for-high-risk-neuroblastoma
#6
Laura K Metrock, Muna Qayed, Dawn Simon, Thomas Cash, Michael G O'Connor, Shaina Johnson, Natia Esiashvili, Howard M Katzenstein
Treatment of high-risk neuroblastoma now includes antibody based antitumor immunotherapy as part of standard care. Although this therapy has resulted in dramatic improvements in survival, it is associated with significant side effects. Children with underlying respiratory issues, and in particular asthma, may be more susceptible to immunotherapy associated respiratory compromise and pulmonary complications. Early routine involvement of pulmonology care is warranted for these patients in an effort to allow maximal delivery of immunotherapy and minimize acute and long-term complications...
January 24, 2017: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/28073701/effect-of-asthma-therapies-on-the-natural-course-of-asthma
#7
REVIEW
Elissa M Abrams, Stanley J Szefler, Allan B Becker
OBJECTIVE: To provide an evidence-based review on the role of pharmacologic (inhaled corticosteroids, leukotriene receptor antagonists, biologic therapies, aeroallergen immunotherapy) and nonpharmacologic therapies (environmental modifications, microbiome) in secondary and tertiary asthma prevention. DATA SOURCES: A PubMed search for English-language publications regarding asthma and secondary or tertiary prevention was performed. Some articles cited in selected studies were also considered for inclusion in this review...
December 2016: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/28065336/sublingual-immunotherapy-dosing-regimens-what-is-ideal
#8
Jay J Jin, James T Li, Ludger Klimek, Oliver Pfaar
Sublingual immunotherapy (SLIT) is a treatment for allergic respiratory diseases that has demonstrated efficacy and safety. Several formulations of SLIT are now available worldwide for treatment of allergic rhinitis (AR). Grass tablets containing 15 to 25 μg of group 5 major allergen reduced combined AR symptoms and medication use by 23% to 41% in 3 treatment years and 2 follow-up years. Ragweed pollen tablets (12 μg of Ambrosia artemisiifolia 1) and liquid extracts (50 μg of Ambrosia artemisiifolia 1) reduced combined AR symptoms and medication use by 26% and 43%, respectively...
January 2017: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28063043/subcutaneous-and-sublingual-immunotherapy-in-a-mouse-model-of-allergic-asthma
#9
Laura Hesse, Martijn C Nawijn
Allergic asthma, caused by inhaled allergens such as house dust mite or grass pollen, is characterized by reversible airway obstruction, associated with an eosinophilic inflammation of the airways, as well as airway hyper responsiveness and remodeling. The inhaled allergens trigger a type-2 inflammatory response with involvement of innate lymphoid cells (ILC2) and Th2 cells, resulting in high production of immunoglobulin E (IgE) antibodies. Consequently, renewed allergen exposure results in a classic allergic response with a distinct early and late phase, both resulting in bronchoconstriction and shortness of breath...
2017: Methods in Molecular Biology
https://www.readbyqxmd.com/read/28049194/early-intervention-improves-clinical-responses-to-house-dust-mite-immunotherapy-in-allergic-rhinitis-patients
#10
Shanshan Qi, Hao Chen, Nan Huang, Wenjing Li, Guanghui Liu, Yin Wang, Lintao Hu, Xiaolong Wang, Wei Zhang, Rongfei Zhu
BACKGROUND: Allergen immunotherapy (AIT) is the unique causal treatment for respiratory allergy. As AIT is expensive and of long duration, the availability of a marker predicting AIT responders is of crucial relevance. OBJECTIVE: To investigate clinical parameters correlated with effective AIT in allergic rhinitis (AR) patients. METHODS: This is a prospective, nonrandomized open study in which a total of 284 AR patients who had received house dust mite (HDM) subcutaneous AIT were enrolled from January 2011 to December 2015, and then followed up for 3 consecutive years...
2016: International Archives of Allergy and Immunology
https://www.readbyqxmd.com/read/28042004/the-potential-role-of-allergen-immunotherapy-in-stepping-down-asthma-treatment
#11
Pascal Demoly, Melina Makatsori, Thomas B Casale, Moises A Calderon
For patients whose asthma is controlled and who have a low risk for future exacerbations, current guidelines recommend gradually stepping down pharmacotherapy to identify the lowest dose needed to maintain control. This review article will discuss the benefits and risks of step down in asthma management and the different strategies of achieving step down with particular focus on allergen immunotherapy (AIT). A literature search was conducted to identify studies that assessed the effect of AIT on asthma step down and evaluated this and asthma control as one of the outcomes...
December 29, 2016: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/28029320/pulmonary-infiltrates-in-a-patient-with-advanced-melanoma
#12
Charles A Powell
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology, to patients seen in their own clinical practice...
March 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/27999674/development-and-validation-of-a-novel-bioassay-to-determine-glucocorticoid-sensitivity
#13
Emily L Williams, Madeleine L Stimpson, Peter L Collins, Doyo G Enki, Ashish Sinha, Richard W Lee, Ashwin D Dhanda
BACKGROUND: Glucocorticoids (GCs) remain the first line treatment for almost all non-infectious inflammatory diseases, ranging from acute asthma to rheumatoid arthritis. However, across all conditions, patients have a variable response to GCs with approximately 30% being non-responders. This group of GC resistant patients is typically exposed to high-dose GCs and their side-effects before more appropriate immunotherapy is instituted. Hence, there is a pressing clinical need for a predictive biomarker of GC responsiveness...
2016: Biomarker Research
https://www.readbyqxmd.com/read/27979028/long-term-effects-of-a-house-dust-mite-sublingual-immunotherapy-tablet-in-an-environmental-exposure-chamber-trial
#14
Petra Zieglmayer, Hendrik Nolte, Harold S Nelson, David I Bernstein, Amarjot Kaur, Henrik Jacobi, Patrick Lemell, René Schmutz, René Zieglmayer, Friedrich Horak
BACKGROUND: Treatment with SQ house dust mite (HDM) sublingual immunotherapy (SLIT) tablet is effective for HDM respiratory allergic disease, but data on long-term effects are lacking. OBJECTIVE: Post hoc analyses were conducted to determine the long-term effect of SQ HDM SLIT-tablet on nasal, ocular, and cough symptoms 1 year after discontinuation of treatment. METHODS: Study participants underwent environmental exposure chamber (EEC) challenges at baseline and week 24 in a randomized, placebo-controlled, double-blind trial (NCT01644617) during which participants received daily 12 SQ-HDM, 6 SQ-HDM, or placebo for 24 weeks...
December 2016: Annals of Allergy, Asthma & Immunology
https://www.readbyqxmd.com/read/27971526/health-economic-evaluation-of-hdm-slit-tablet-for-allergen-immunotherapy-in-house-dust-mite-induced-allergic-rhinitis-with-or-without-allergic-asthma-in-an-italian-setting
#15
G Cadario, M Maspoli, S Di Matteo, M C Valentino, M Oselin, G M Bruno, G L Colombo
No abstract text is available yet for this article.
November 2016: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/27965111/sialylated-fetuin-a-as-a-candidate-predictive-biomarker-for-successful-grass-pollen-allergen-immunotherapy
#16
Noémie Caillot, Julien Bouley, Karine Jain, Sandrine Mariano, Sonia Luce, Stéphane Horiot, Sabi Airouche, Chloé Beuraud, Christian Beauvallet, Philippe Devillier, Sylvie Chollet-Martin, Christine Kellenberger, Laurent Mascarell, Henri Chabre, Thierry Batard, Emmanuel Nony, Vincent Lombardi, Véronique Baron-Bodo, Philippe Moingeon
BACKGROUND: Eligibility to immunotherapy is based on the determination of IgE reactivity to a specific allergen by skin prick or in vitro testing. Biomarkers predicting the likelihood of clinical improvement during immunotherapy would significantly improve patient selection. METHODS: Proteins were differentially assessed by 2D-DiGE and label-free mass spectrometry in pre-treatment sera obtained from clinical responders and non-responders within a cohort of 82 grass pollen allergic patients receiving sublingual immunotherapy or placebo...
December 10, 2016: Journal of Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/27957697/benefit-of-slit-and-scit-for-allergic-rhinitis-and-asthma
#17
REVIEW
Giovanni Passalacqua, Giorgio Walter Canonica, Diego Bagnasco
Allergen immunotherapy (AIT) has been in use since more than one century, when Leonard Noon experimentally proved its efficacy in hayfever (Noon, in Lancet 1:1572-3, 1911). Since then, AIT was administered only as subcutaneous injections (SCIT) until the sublingual route (SLIT) was proposed in 1986. The use of SLIT was proposed following several surveys from the USA and UK that repeatedly reported fatalities due to SCIT (Lockey et al. in J Allergy Clin Immunol 75(1): 166, 1985; Lockey et al. in J Allergy Clin Immunol 660-77, 1985; Committee on the safety of medicines...
November 2016: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/27943047/epigenetic-changes-during-food-specific-immunotherapy
#18
REVIEW
Bryan J Bunning, Rosemarie H DeKruyff, Kari C Nadeau
PURPOSE OF REVIEW: The prevalence and severity of IgE-mediated food allergy has increased dramatically over the last 15 years and is becoming a global health problem. Multiple lines of evidence suggest that epigenetic modifications of the genome resulting from gene-environment interactions have a key role in the increased prevalence of atopic disease. In this review, we describe the recent evidence suggesting how epigenetic changes mediate susceptibility to food allergies, and discuss how immunotherapy (IT) may reverse these effects...
November 2016: Current Allergy and Asthma Reports
https://www.readbyqxmd.com/read/27942351/therapeutic-interventions-in-severe-asthma
#19
REVIEW
Giorgio Walter Canonica, Gianenrico Senna, Patrick D Mitchell, Paul M O'Byrne, Giovanni Passalacqua, Gilda Varricchi
The present paper addresses severe asthma which is limited to 5-10% of the overall population of asthmatics. However, it accounts for 50% or more of socials costs of the disease, as it is responsible for hospitalizations and Emergency Department accesses as well as expensive treatments. The recent identification of different endotypes of asthma, based on the inflammatory pattern, has led to the development of tailored treatments that target different inflammatory mediators. These are major achievements in the perspective of Precision Medicine: a leading approach to the modern treatment strategy...
2016: World Allergy Organization Journal
https://www.readbyqxmd.com/read/27939406/safety-of-immunotherapy-with-glutaraldehyde-modified-allergen-extracts-in-children-and-adults
#20
M Guzmán-Fulgencio, R Caballero, B Lara, M Mena, M Tejera, A Sastre, J-L Subiza, E Fernández-Caldas, M Casanovas
BACKGROUND: Glutaraldehyde-modified natural allergen extracts show significant reduction in the IgE-binding capacity and proteolytic activity. This allows the administration of higher doses in a shorter period of time, and to mix different allergen extracts. OBJECTIVE: Evaluate the safety of different concentrations and mixtures of glutaraldehyde-modified allergen extracts in a large group of paediatric and adult patients undergoing specific immunotherapy treatment...
December 7, 2016: Allergologia et Immunopathologia
keyword
keyword
15390
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"